CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Nov

Today In Oncology

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

HER2-Positive Targeted Therapy Cardiovascular Risk: ACC Upcoming Journal Club

Upcoming ASCO AI in Oncology Webinar Turns Chatbot Printouts Into Better Patient Conversations

Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control

Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer

A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery